Latest News

Canopy Growth Stock Jumps After Earnings, Despite Slowing Marijuana Sales

0
Text size

Marijuana plants at a Canopy Growth facility in Ontario.
Chris Roussakis/Bloomberg

Canopy Growth‘s shares were jumping Wednesday after the Canadian cannabis company reported higher-than-expected revenue as sales of its other products helped offset a year-over-year decline in Canadian sales of marijuana.

Canopy (ticker: CGC) posted a loss of 28 Canadian cents a share, or 22 U.S. cents, in line with analysts’ predictions, for the three months ended in December. Revenue in the third quarter of Canopy’s fiscal 2022 quarter was C$141 million, above analysts’ expectations for C$135.9 million.

The company’s U.S.-listed shares were up 12.7%, at $8.67, in recent trading. Before today, they had declined 12% year to date.

Canopy said its consumer-products business had a record performance both from BioSteel, a recently acquired sports hydration business, and Storz & Bickel, its medical vaporizer arm, while it begins to stabilize its Canadian cannabis business.

BioSteel and Storz & Bickel achieved record quarterly revenue of C$17 million and C$25.2 million, respectively. The hydration maker’s revenue was 130% higher than the third quarter of fiscal 2021, driven by expanded distribution. Storz & Bickel had new product launches, the company said.

MKM Partners analyst Bill Kirk said that the beat—albeit soft—was much needed. Expectations for Canopy have grown progressively less upbeat, and because the stock has fallen some 44% over the past three months, investors will view the results positively. Kirk has a Buy rating and a C$17 price target on the stock. When Canopy reported its second-quarter results, it pushed out its target for when it will achieve its positive adjusted Ebitda target partly due to market-share challenges in the Canadian recreational business. (Ebitda stands for earnings before interest, taxes, depreciation, and amortization.)

Overall revenue in the quarter was 8% lower than in the year-earlier quarter due to a decline in Canadian cannabis sales. Canadian cannabis revenue, both recreational and medical, was down 21% to C$60.7 million versus last year. Global net revenue from cannabis was C$83 million, down 20% from the same quarter a year earlier.

“With a renewed sense of urgency, we are focused on achieving profitability in Canada by taking additional steps to simplify our business and optimize our expenses, while making strategic investments in key growth areas,” said interim Chief Financial Officer Judy Hong.

Kirk argues that the U.S. is ultimately the best opportunity for the company. “The timing of U.S. THC [legalization] is uncertain but is worth more than all other markets combined,” he said.

Write to Karishma Vanjani at karishma.vanjani@dowjones.com

How to profit from your losses on those ‘Cathie Wood’ stocks

Previous article

Playing It Safe? The Best Conservative Investments for 2022

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News